Status:

TERMINATED

Effects of a Food Supplement Composed by BIOintestil ® (Bionocol®) on Microbiota and Inflammatory Profile in Irritable Bowel Syndrome Patients

Lead Sponsor:

Targeting Gut Disease S.R.L.

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The aim of this double blind placebo-controlled study is to evaluate the effect of BIOintestil on fecal microbiota, inflammatory chemokines and symptoms in patients affected by Irritable Bowel Syndrom...

Detailed Description

BIOintestil is a dietary supplement based on Palmrose oil (Cymbopogon martinii) and ginger ryzoma powder. Palmrose oil effects were already established in animal model of colitis and in a pilot study ...

Eligibility Criteria

Inclusion

  • willing of sign written informed consent;
  • participants affected with Irritable bowel syndrome (IBS) who satisfy Rome III criterias for diagnosis
  • body weight between 48 and 104 kg, with a BMI less than 27
  • age between 18 and 65 years old

Exclusion

  • participants that have not taken following medications within 30 days before randomization: steroidal anti-inflammatory drugs, antibiotics or supplemntes or functional foods that may contain probiotics or prebiotics
  • women who suspect to be/are pregnant or in lactacy
  • participants with Inflammatory bowel disease disgnosis or celiac disease or severe systemic disease
  • participants who are intolerant to lactose or with food allergies confirmed
  • particpiants with confirmed or suspected hypersensibility to one or more of Bionocol® components
  • participants with severe concomitants disease that, by investigator's opinion, interfere with study partecipation
  • participants under anticoagulant therapy or with coagulation disease
  • participants with renal and hepatic failure
  • participants who have taken any investigational drug within 2 month the randomization visit

Key Trial Info

Start Date :

December 5 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2021

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT04340661

Start Date

December 5 2018

End Date

January 31 2021

Last Update

April 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

A.O.U Policlinico S.Orsola-Malpighi

Bologna, Italy, 40138